Global Isatuximab Market Strategic Research Report

Scope of the Report

The global Isatuximab market size is predicted to grow from US$ 616 million in 2025 to US$ 1,731 million in 2032; it is expected to grow at a CAGR of 14.6% from 2026 to 2032.

Isatuximab is a humanized monoclonal antibody targeting CD38, primarily used in the treatment of hematologic malignancies such as multiple myeloma. It exerts its anti-tumor effects by specifically binding to the CD38 antigen expressed on the surface of tumor cells, thereby inducing multiple immune-mediated mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of tumor cell apoptosis. Isatuximab is typically used in combination with immunomodulatory agents or proteasome inhibitors for patients with relapsed or refractory multiple myeloma, and has significant clinical value in the field of hematologic cancer targeted therapy.In 2025, global Isatuximab production reached approximately 120,000 units.

Isatuximab, as a CD38-targeting monoclonal antibody, holds an important position in the treatment market for multiple myeloma. With the acceleration of global aging and the gradual increase in the incidence of multiple myeloma, the demand for hematologic cancer therapies continues to grow, driving the expansion of the CD38-targeted drug market. Isatuximab has steadily increased its market penetration due to its clinical efficacy in relapsed or refractory patients and its growing use in frontline combination therapy regimens. From a competitive landscape perspective, this field is primarily dominated by early entrants such as daratumumab. However, Isatuximab is gradually gaining market share through differentiated clinical data and combination treatment strategies. Looking ahead, with the approval of more frontline indications, the standardization of combination therapies, and further expansion into global markets, the market size of Isatuximab is expected to maintain steady growth, continuing to play an important role in the CD38-targeted therapy landscape.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Isatuximab market?

What factors are driving Isatuximab market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Isatuximab market opportunities vary by end market size?

How does Isatuximab break out by Type, by Application?

This report presents a comprehensive overview of the global Isatuximab market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Monoclonal Antibody, mAb
• Polyclonal Antibody, pAb

Segment by Specification

• 100 mg / 5 mL
• 500 mg / 25 mL

Segment by Route of Administration

• Hospital
• Retail
• Online

Segment by Application

• Relapsed or Refractory Multiple Myeloma (R/R MM)
• Frontline Multiple Myeloma (Frontline MM)
• CD38-Positive Hematologic Malignancies
• Precision Hematologic Cancer Therapy
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Isatuximab market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Relapsed or Refractory Multiple Myeloma (R/R MM), Frontline Multiple Myeloma (Frontline MM), CD38-Positive Hematologic Malignancies evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact